Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 9/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.34 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604966 | 0.85 | GRM5 (0.38) | TRPM8KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL4605578 | 0.84 | ADORA3 (0.42) | KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL4606677 | 0.78 | ALDH1A1 (0.33) | KDM4ESMN1; SMN2 | |
| SCHEMBL4606464 | 0.78 | GRK6 (0.30) | — | |
| SCHEMBL4604129 | 0.74 | TRPM8 (0.39) | TRPM8KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL4606567 | 0.72 | ALDH1A1 (0.38) | KDM4ESMN1; SMN2 | |
| SCHEMBL5412658 | 0.69 | KMO (0.46) | KDM4ESMN1; SMN2 | |
| SCHEMBL4606264 | 0.67 | ADORA3 (0.45) | KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL4607588 | 0.67 | KDM4E (0.43) | CHRNA7TRPM8KDM4ESMN1; SMN2ADORA3 | |
| SCHEMBL6364194 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1574505-B1 | 1,2,4-THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL CO (JP) | 2008-07-16 | — | — | EP | disclosed |
| US-7361675-B2 | 1,2,4-thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2008-04-22 | — | — | US | disclosed |
| US-20060167266-A1 | 1,2,4- thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-07-27 | — | — | US | disclosed |
| EP-1574505-A1 | 1,2,4-THIADIAZOLE COMPOUNDS AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167266-A1 | 1,2,4- thiadiazole compounds and use thereof | CBR3, CBR1, NOX3 | CHRNA7 1039/4885TRPM8 3602/4885KDM4E 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.